HCMED (6934) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 心誠鎂

HCMED (6934) reported revenue of NT$44,000 for Oct 2026, -88.5% year on year and -99.9% from the previous month. Revenue for Jan–Oct 2026 was NT$54.7 million (+201.7% year on year).

In Oct 2026, it ranked No. 153 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$101.7 million24/10Nov 2024 NT$2.1 millionDec 2024 NT$1.4 millionJan 2025 NT$349,000Feb 2025 NT$205,00025/02Mar 2025 NT$7.7 millionApr 2025 NT$697,000May 2025 NT$1.9 millionJun 2025 NT$28,00025/06Jul 2025 NT$3.1 millionAug 2025 NT$49,000Sep 2025 NT$3.8 millionOct 2025 NT$381,00025/10Nov 2025 NT$70.8 millionDec 2025 NT$11.3 millionJan 2026 NT$41,000Feb 2026 NT$18,00026/02Mar 2026 NT$3.6 millionApr 2026 NT$4.5 millionMay 2026 NT$22,000Jun 2026 NT$11.6 million26/06Jul 2026 NT$48,000Aug 2026 NT$41,000Sep 2026 NT$34.8 millionOct 2026 NT$44,00026/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$44,000-88.5%-99.9%
Sep 2026NT$34.8 million+822.9%+84,690.2%
Aug 2026NT$41,000-16.3%-14.6%
Jul 2026NT$48,000-98.4%-99.6%
Jun 2026NT$11.6 million+41,325.0%+52,622.7%
May 2026NT$22,000-98.8%-99.5%
Apr 2026NT$4.5 million+546.6%+24.3%
Mar 2026NT$3.6 million-53.1%+20,044.4%
Feb 2026NT$18,000-91.2%-56.1%
Jan 2026NT$41,000-88.3%-99.6%
Dec 2025NT$11.3 million+721.3%-84.1%
Nov 2025NT$70.8 million+3,217.2%+18,488.7%
Oct 2025NT$381,000-99.6%-89.9%
Sep 2025NT$3.8 million+3.2%+7,587.8%
Aug 2025NT$49,000-95.6%-98.4%
Jul 2025NT$3.1 million-76.1%+10,910.7%
Jun 2025NT$28,000-99.2%-98.5%
May 2025NT$1.9 million-39.9%+165.7%
Apr 2025NT$697,000-82.9%-91.0%
Mar 2025NT$7.7 million+103.9%+3,667.8%
Feb 2025NT$205,000-90.7%-41.3%
Jan 2025NT$349,000-85.2%-74.6%
Dec 2024NT$1.4 million-46.8%-35.7%
Nov 2024NT$2.1 million-16.3%-97.9%
Oct 2024NT$101.7 million+26,049.6%+2,686.9%

Jan–Oct 2026 cumulative: NT$54.7 million (+201.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: HCMED vs PEC / HCMED vs Lotus Pharm / HCMED vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

差異主係本公司9月完成與新藥廠客戶簽約所依約完成事項而取得的勞務報酬所致;勞務報酬非定期,依照合約進行並認列。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16